Illinois SB1773 amendment filed (sam003) detailing xylazine exemptions for veterinary/animal-drug and certain professional uses

An Illinois SB1773 committee amendment (sam003), filed 2025-04-01, provides detailed statutory exemption language (new Section 309.1) stating that, notwithstanding the Schedule/Class III scheduling of xylazine, xylazine is not considered a controlled substance when used/handled under specified conditions (including certain licensed veterinarian use for nonhuman species involving FDA-approved animal drugs, use as an API for manufacturing an FDA-approved animal drug, use by licensed certified euthanasia technicians employed by certified euthanasia agencies, and wildlife biologist fieldwork under indirect veterinarian supervision). Compliance teams should use the amendment text to assess whether current/anticipated xylazine activities would fall under exemptions if SB1773 is enacted.